Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer
This study evaluates the efficacy and safety of DWJ1319 in the prevention of gallstone formation after gastrectomy in patient with gastric cancer. Two-thirds of the participants will receive DWJ1319, while the other will receive a placebo.
Gastric Cancer
DRUG: DWJ1319|DRUG: Placebo
Proportion of patient developing gallstone at 12 month after gastrectomy, 12 months
Proportion of patient developing gallstone at 3, 6 and 9 month after gastrectomy, 3, 6 and 9 months|Time to gallstone formation, 12 months
This study evaluates the efficacy and safety of DWJ1319 in the prevention of gallstone formation after gastrectomy in patient with gastric cancer. Two-thirds of the participants will receive DWJ1319, while the other will receive a placebo.